Median Technologies Secures FDA Clearance, Eyes European Expansion for Lung Cancer AI
Event summary
- Median Technologies received FDA 510(k) clearance for its eyonis® LCS AI-powered software for lung cancer screening on February 9, 2026.
- The company entered a distribution agreement with Tempus AI to expand access to eyonis® LCS in the U.S. and potentially Europe.
- Oran Muduroglu was appointed President of Median eyonis Inc., the company’s U.S. subsidiary, on February 18, 2026.
- Median Technologies reported €23.4 million in revenue for full-year 2025, with an order backlog of €79.8 million as of March 31, 2026.
- The company has €14.0 million in cash as of March 31, 2026, with potential for €44 million more through warrant exercises.
The big picture
Median Technologies is positioned to capitalize on the growing demand for AI-powered diagnostic tools in oncology, particularly with the FDA clearance for eyonis® LCS. The partnership with Tempus AI expands reach within the U.S. market, but the company's success hinges on rapid commercialization and navigating regulatory hurdles in Europe. The substantial order backlog for iCRO services provides a degree of revenue visibility, but the company must balance this with continued investment in its SaMD portfolio.
What we're watching
- Commercialization
- The speed of adoption of eyonis® LCS in the U.S. market will be critical, as the company anticipates first sites operational in Q3 2026 and revenue generation by year-end. Early adoption rates will dictate the success of the go-to-market strategy.
- Regulatory Risk
- The anticipated CE marking decision in Q2 2026 for eyonis® LCS represents a key milestone for European expansion; a delay or denial could significantly impact growth projections.
- Financial Runway
- While the current cash position and potential warrant exercises provide a runway through year-end 2026, the company's ability to achieve profitability and generate sustained revenue will be essential to avoid future financing needs.
Related topics